TÜBINGEN / BERLIN, Germany, July 31, 2017 – The 5th International mRNA Health Conference, taking place on November 1-2 in Berlin, Germany, is the premier meeting destination for professionals and academia in the field of mRNA drugs. In its fifth year, the conference is returning to Berlin to celebrate the remarkable research, preclinical and clinical progress of the past year. The event will provide participants an opportunity to attend scientific presentations given by the most esteemed experts in the field, secure updates on advances in mRNA technology, and to network with colleagues.
Hundreds of world renowned innovators, scientists, academia and pharmaceutical delegates are expected to attend the conference as mRNA therapeutic technology evolves from scientific concept to medical application. Approximately 25 speakers will present on preclinical and clinical development in the fields of oncology, infectious diseases and molecular therapies as well as mRNA delivery, design and product development. Additionally, a poster session will provide research groups and company representatives the opportunity to showcase their data to attendees.
Ingmar Hoerr, Ph.D., founding member of the International mRNA Health Conference and CEO of CureVac, commented, “The mRNA industry has witnessed a multitude of transformational events over the past twelve months, with multiple programs being pushed through the clinic and companies developing infrastructure to prepare for eventual commercialization efforts. It seems that every year since our colleagues from Moderna, BioNTech and we began hosting this meeting, we grow substantially closer to realizing mRNA as an actual medical application. Academics and industry continue to break new ground in understanding the vast potential of the technology across multiple therapeutic fields. With the conference entering its fifth year, we are delighted to welcome our colleagues in the field to celebrate another successful year of mRNA research and development as we bring our vision closer to realization.”
The 5th International mRNA Health Conference